Insider Trading Alert - TRLA, CMS And TMO Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, April 30, 2014, 84 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $105.05 to $21,917,679.52.

Highlighted Stocks Traded by Insiders:

Trulia (TRLA) - FREE Research Report

Inkinen Sami, who is Director at Trulia, sold 5,800 shares at $30.38 on April 30, 2014. Following this transaction, the Director owned 747,853 shares meaning that the stake was reduced by 0.77% with the 5,800-share transaction.

Flint Peter, who is Chief Executive Officer at Trulia, sold 9,200 shares at $30.66 on April 30, 2014. Following this transaction, the Chief Executive Officer owned 1.4 million shares meaning that the stake was reduced by 0.64% with the 9,200-share transaction.

The shares most recently traded at $34.72, up $4.06, or 11.69% since the insider transaction. Historical insider transactions for Trulia go as follows:

  • 4-Week # shares sold: 48,750
  • 12-Week # shares sold: 227,943
  • 24-Week # shares sold: 457,034

The average volume for Trulia has been 2.0 million shares per day over the past 30 days. Trulia has a market cap of $1.2 billion and is part of the technology sector and internet industry. Shares are down 3.6% year-to-date as of the close of trading on Wednesday.

Trulia, Inc. provides tools to research homes and neighborhoods for consumers through Web and mobile applications. The company, through its tools, also enables real estate professionals to market their listings. Currently, there are 4 analysts who rate Trulia a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on TRLA - FREE

TheStreet Quant Ratings rates Trulia as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. Get the full Trulia Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

CMS Energy (CMS) - FREE Research Report

Mengebier David G, who is Senior Vice President at CMS Energy, sold 3,100 shares at $29.91 on April 30, 2014. Following this transaction, the Senior Vice President owned 125,054 shares meaning that the stake was reduced by 2.42% with the 3,100-share transaction.

The shares most recently traded at $29.96, up $0.05, or 0.17% since the insider transaction. Historical insider transactions for CMS Energy go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 35,000
  • 24-Week # shares bought: 3,000
  • 24-Week # shares sold: 35,000

The average volume for CMS Energy has been 2.4 million shares per day over the past 30 days. CMS Energy has a market cap of $8.1 billion and is part of the utilities sector and utilities industry. Shares are up 12.36% year-to-date as of the close of trading on Wednesday.

CMS Energy Corporation, through its subsidiaries, operates as an energy company primarily in Michigan, the United States. The company operates in three segments: Electric Utility, Gas Utility, and Enterprises. The stock currently has a dividend yield of 3.73%. The company has a P/E ratio of 17.4. Currently, there are 4 analysts who rate CMS Energy a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CMS - FREE

TheStreet Quant Ratings rates CMS Energy as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, notable return on equity, increase in net income and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full CMS Energy Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Thermo Fisher Scientific (TMO) - FREE Research Report

Manzi Jim P, who is Director at Thermo Fisher Scientific, sold 3,000 shares at $114.85 on April 30, 2014. Following this transaction, the Director owned 40,997 shares meaning that the stake was reduced by 6.82% with the 3,000-share transaction.

The shares most recently traded at $114.27, down $0.58, or 0.51% since the insider transaction. Historical insider transactions for Thermo Fisher Scientific go as follows:

  • 4-Week # shares sold: 4,994
  • 12-Week # shares sold: 86,431
  • 24-Week # shares sold: 86,431

The average volume for Thermo Fisher Scientific has been 2.6 million shares per day over the past 30 days. Thermo Fisher Scientific has a market cap of $45.7 billion and is part of the health care sector and health services industry. Shares are up 2.38% year-to-date as of the close of trading on Wednesday.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics in the United States and internationally. The stock currently has a dividend yield of 0.48%. The company has a P/E ratio of 35.4. Currently, there are 13 analysts who rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TMO - FREE

TheStreet Quant Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, compelling growth in net income and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Thermo Fisher Scientific Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

Obama Senior Advisor Jarrett Joins Lyft's Board

Obama Senior Advisor Jarrett Joins Lyft's Board

Doug Kass -- Beware of Facebook's Earnings GAAP

Doug Kass -- Beware of Facebook's Earnings GAAP

Avoid Zillow Until Concerns About Its Business Model Are Resolved

Avoid Zillow Until Concerns About Its Business Model Are Resolved

Plotting Strategy on Zillow

Plotting Strategy on Zillow

Cramer: Trulia Deal Shows Zillow CEO Has Many 'Irons in the Fire'

Cramer: Trulia Deal Shows Zillow CEO Has Many 'Irons in the Fire'